UroGen Pharma Ltd. (URGN)
NASDAQ: URGN
· Real-Time Price · USD
16.93
-0.36 (-2.08%)
At close: Oct 16, 2025, 3:59 PM
17.56
3.72%
After-hours: Oct 16, 2025, 07:16 PM EDT
-2.08% (1D)
| Bid | 16.35 |
| Market Cap | 783.25M |
| Revenue (ttm) | 94.24M |
| Net Income (ttm) | -154.97M |
| EPS (ttm) | -3.06 |
| PE Ratio (ttm) | -5.53 |
| Forward PE | -20.81 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 17.65 |
| Volume | 801,719 |
| Avg. Volume (20D) | 1,225,607 |
| Open | 17.50 |
| Previous Close | 17.29 |
| Day's Range | 16.91 - 17.64 |
| 52-Week Range | 3.42 - 21.71 |
| Beta | 1.02 |
| Ex-Dividend Date | n/a |
About URGN
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol URGN
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for URGN stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsUroGen Pharma Ltd. is scheduled to release its earnings on
Nov 5, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
4 months ago
+8.57%
UroGen Pharma shares are trading higher after Gugg...
Unlock content with
Pro Subscription
4 months ago
+51.78%
UroGen Pharma shares are trading higher after the FDA approved ZUSDURI for intravesical solution a the first and only medication for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer.
